This content is in French.
Camrelizumab + Apatinib: a winning combo against TNBC?
29 octobre 2025
By Ana Espino | Published on October 29, 2025 | 2 min readTriple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, often affecting younger women. It is characterized by the absence of hormone receptors and HER2 overexpression, as well as a strong propensity for early metastatic relapse—especially within the first few years after diagnosis. Because it is unrespo
Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, often affecting younger women. It is characterized by the absence of hormone receptors and HER2 overexpression, as well as a strong propensity for early metastatic relapse—especially within the first few years after diagnosis. Because it is unresponsive to conventional targeted therapies, patients with TNBC are left with limited effective treatment options.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Liu, X., et al. (2025). Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for TNBC […]. Signal transduction and targeted therapy, 10(1), 237.
View the source
